Literature DB >> 29798815

Development of a Model to Predict Invasiveness in Ductal Carcinoma In Situ Diagnosed by Percutaneous Biopsy-Original Study and Critical Evaluation of the Literature.

Maíra Teixeira Dória1, Jonathan Yugo Maesaka2, Raymundo Soares de Azevedo Neto3, Nestor de Barros4, Edmund Chada Baracat2, José Roberto Filassi2.   

Abstract

BACKGROUND: Approximately 30% of ductal carcinoma in situ (DCIS) cases have an invasive component discovered on the final analysis that could affect surgical management. The aims of the present study were to determine the risk factors associated with the underestimation of DCIS and to develop a model to predict the probability of invasiveness.
MATERIALS AND METHODS: A retrospective analysis was performed on the data for all patients with a diagnosis of DCIS found by percutaneous biopsy from January 2008 to February 2016. Thirteen potential predictors of invasiveness were examined. The statistical analysis of the present study was improved using Nagelkerke's R2, the area under the receiving operating characteristic (AUC) curve, and the Hosmer-Lemeshow goodness-of-fit test.
RESULTS: Of 354 biopsy specimens deemed to be DCIS on initial biopsy, 100 (28.2%) were recategorized as invasive carcinoma after surgery. On multivariate analysis, the strongest predictors of invasiveness were comedonecrosis, size on mammography, suspected microinvasion, histologic grade, and younger patient age. The model had a good discriminative ability, with an AUC of 0.764. The overall performance of the model was fair, with a Nagelkerke's R2 of 40.9%. A separate analysis performed on 274 specimens obtained through vacuum-assisted biopsy revealed different variables were associated with underestimation; however, a similar AUC (0.743) and Nagelkerke's R2 (45.7%) were obtained.
CONCLUSION: Our model had the best AUC for predicting DCIS invasiveness reported to date. However, further statistical analysis showed only a fair overall performance. The currently known clinical, radiographic, and pathologic features might be insufficient to identify which patients with DCIS have underestimated disease.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast neoplasm; DCIS; Intraductal carcinoma; Invasive; Sentinel lymph node biopsy

Mesh:

Year:  2018        PMID: 29798815     DOI: 10.1016/j.clbc.2018.04.011

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN: 1526-8209            Impact factor:   3.225


  5 in total

1.  Ductal carcinoma in situ on digital mammography versus digital breast tomosynthesis: rates and predictors of pathologic upgrade.

Authors:  Geunwon Kim; Peter G Mikhael; Tawakalitu O Oseni; Manisha Bahl
Journal:  Eur Radiol       Date:  2020-06-26       Impact factor: 5.315

2.  Breast Microinvasive Carcinoma With Different Morphologies: Analysis of Clinicopathologic Features of 121 Cases.

Authors:  ChangYin Feng; QiaoLing Zheng; YingHong Yang
Journal:  Breast Cancer (Auckl)       Date:  2020-10-05

3.  Everolimus Inhibits the Progression of Ductal Carcinoma In Situ to Invasive Breast Cancer Via Downregulation of MMP9 Expression.

Authors:  Guang Chen; Xiao-Fei Ding; Kyle Pressley; Hakim Bouamar; Bingzhi Wang; Guixi Zheng; Larry E Broome; Alia Nazarullah; Andrew J Brenner; Virginia Kaklamani; Ismail Jatoi; Lu-Zhe Sun
Journal:  Clin Cancer Res       Date:  2019-12-23       Impact factor: 12.531

4.  Breast Lesions Diagnosed as Ductal Carcinoma In Situ by Ultrasound-Guided Core Needle Biopsy: Risk Predictors for Concomitant Invasive Carcinoma and Axillary Lymph Node Metastasis.

Authors:  Yanbiao Liu; Xu Wang; Ang Zheng; Xinmiao Yu; Zining Jin; Feng Jin
Journal:  Front Oncol       Date:  2021-09-10       Impact factor: 6.244

5.  Pathological underestimation and biomarkers concordance rates in breast cancer patients diagnosed with ductal carcinoma in situ at preoperative biopsy.

Authors:  Hemei Zhou; Jing Yu; Xiaodong Wang; Kunwei Shen; Jiandong Ye; Xiaosong Chen
Journal:  Sci Rep       Date:  2022-02-09       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.